Inherited metabolic diseases impose a significant worldwide burden both financially and socially. Although there have been advances in treating these disorders, alternative therapeutic approaches are being developed to correct the responsible genetic defects. Gene augmentation using viral vectors and transgene expression to replace an absent or defective protein has shown limited success in treating a variety of genetic disorders. In fact, the mechanisms by which cells and organisms protect against viral infections have presented significant barriers for long-term stable expression of the introduced transgene. In part, due to the disadvantages of using biological vectors, a variety of different approaches for nonviral gene delivery have been developed. 1 In particular, targeting of nonviral delivery systems to specific tissues by receptor/ligand interactions has been exploited for in vivo gene transfer.
Inherited metabolic diseases impose a significant worldwide burden both financially and socially. Although there have been advances in treating these disorders, alternative therapeutic approaches are being developed to correct the responsible genetic defects. Gene augmentation using viral vectors and transgene expression to replace an absent or defective protein has shown limited success in treating a variety of genetic disorders. In fact, the mechanisms by which cells and organisms protect against viral infections have presented significant barriers for long-term stable expression of the introduced transgene. In part, due to the disadvantages of using biological vectors, a variety of different approaches for nonviral gene delivery have been developed. 1 In particular, targeting of nonviral delivery systems to specific tissues by receptor/ligand interactions has been exploited for in vivo gene transfer. 2 By targeting the asialoglycoprotein receptor (ASGPR), gene delivery to hepatocytes has been significantly improved both in vitro 3 and in vivo. 4, 5 Thus, we have focused on using nonviral approaches to correct the genetic defect in hepatocytes using galactosylated Correspondence: BT Kren compounds attached directly to polycations, or incorporated in liposomes. 6 The strategy of in situ genomic repair using chimeric RNA/DNA molecules (chimeraplasts) developed from studies investigating molecular aspects of DNA repair. It became apparent that there was a significant increase in pairing efficiency between an oligonucleotide Յ50 bases and a genomic DNA target if RNA replaced DNA in a portion of the targeting oligonucleotide. 7, 8 The original chimeric 68-mer design incorporated 10 2'-O-methylated RNA residues flanking each side of a 5 bp stretch of DNA, poly-T hairpin loops, a 3' GC clamp and a complementary all-DNA strand resulting in a stable, nucleaseresistant duplex molecule. The 25 bp homology segment between the chimeraplast and its genomic target is constructed such that it includes one mismatch with the DNA sequence of the gene. This engineered mismatch permits the directed alteration of the genomic target using the chimeraplast as a template for the intended correction of target sequence. It is postulated that the 'mismatched' chimeraplast complexes with the genomic DNA and creates the illusion of a genetic mutation leading to the recruitment of endogenous repair functions. 9, 10 This novel approach of gene repair, based on in vitro experimental evidence, was shown by Yoon et al 11 and Cole-Strauss et al 12 to be capable of introducing targeted single base conversions in episomal and genomic DNA in cultured cells. We then reported that the chimeraplast technology could introduce a missense mutation in genomic DNA in human hepatoma cells, 13 and nonreplicating isolated rat hepatocytes. 14 The high rates of nucleotide conversion observed in primary hepatocytes resulted, in part, from significantly improved delivery of chimeraplasts using our modified nonviral-ASGPR receptor targeted delivery systems. 15, 16 Chimeraplasts were shown to mediate site-specific base changes in genomic DNA of primary rat hepatocytes independently of DNA and/or cell replication, suggesting the potential for in vivo use.
Thus, chimeraplasts were designed to introduce a single base mutation in the rat factor IX protein, rendering it nonfunctional. They were targeted for uptake by the ASGPR on hepatocytes by either encapsulation in anionic liposomes containing galactocerebroside or complexed with the polycation, polyethylenimine (PEI), covalently linked to lactose. The chimeraplast delivery systems were administered by tail vein injection either as a single dose or repeated doses on consecutive days. DNA was isolated from liver tissue and subjected to PCR amplification of the target region for analysis by duplicate filter lift hybridization. A genomic A-to-C conversion frequency of 48.7 ± 10.4% was observed 1 week after treatment, and this remained invariant through 18 weeks. 16 A similar decrease in factor IX activity was determined by an modified assay for activated partial thromboplastin time. These changes remained stable for 2 years in both quiescent and regenerated liver after 70% partial hepatectomy. In this model of cell replication, the remaining hepatocytes undergo at least two rounds of replication to reestablish liver mass. 17, 18 We used a similar strategy with a 76-mer chimeraplast containing a 9 base DNA segment in the hybrid strand, to correct the single base deletion of the UGT1A1 gene in the Gunn rat model of Crigler-Najjar syndrome type 1.
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The deletion of a single guanosine residue in the UGT1A1 gene results in the loss of a BstNI restriction endonuclease site, and introduction of a premature stop codon resulting in the loss of UGT1A1 enzymatic activity and hyperbilirubinemia. 20, 21 Following two treatments with chimeraplasts designed to replace the deleted base pair, filter lift hybridizations, restriction fragment length polymorphisms and Southern analysis confirmed that UGT1A1 mutation was corrected in >20% of the gene pool in the liver. 19 In addition, the genotypic repair reestablished UGT1A1 protein expression (Figure 1 ), enzymatic function, bilirubin glucuronidation, and reduced bilirubin levels >50% in the serum of the Gunn rats ( Table  1 ). The decrease in serum bilirubin levels was visually apparent after the treatment course ( Figure 2) . Moreover, each of these parameters remained stable for the entire 2-year study period. 18 It is now well known that not all human genetic diseases result from defects in the nuclear genome. In fact, some disorders are known to be associated with mitochondrial DNA defects such as Leber's hereditary optic neuropathy 22 and certain forms of encephalopathy and myopathy. 23 Although it has been demonstrated in cellfree systems that nuclei contain the essential factors for DNA repair, 24 mitochondria have been shown to be defective in certain forms of DNA repair. 25 Therefore, we used chimeraplast-mediated gene modification in bacteria (Escherichia coli) containing a plasmid-encoded antibiotic resistance to characterize the mechanism and some of the key factors required for targeted single nucleotide conversion. 26 These studies suggested that mitochondria, as an organelle of bacterial descent, might possess the enzymatic machinery essential for site-specific nucleotide repair. Therefore, we determined whether mitochondria possess the necessary factors for chimeraplast-mediated DNA changes using a polymerase chain reaction (PCR)-independent cell-free extract system to test for DNA repair.
The methods employ a bacterial read-out system based on correction of plasmid encoded mutant alleles. 27 The first cell-free system utilized a dual antibiotic resistance selection scheme. One antibiotic resistance gene contains the point mutation targeted for correction by the chimeraplasts. If correction of the targeted mutation occurs, the plasmid then confers resistance, permitting growth of the transformed bacteria on medium containing both antibiotics. The mutation in the antibiotic resistance also introduces a new BfaI restriction endonuclease site, the loss of which can be used to establish conversion of the targeted base. Following incubation of the plasmid, cell extract and chimeraplasts designed to correct the mutation in antibiotic resistance, the recovered plasmids are used for transformation. RecA or MutS deficient strains are transformed, as these gene products have been shown to be essential for chimeraplast-mediated repair in bacteria. 26 Extracts were prepared from nuclei and highly purified mitochondria isolated from rat liver, and the authenticity and purity of the extracts established by Western blot, enzymatic activity and electron microscopy. [28] [29] [30] Using this PCR-independent bacterial read-out system and extracts derived from rat liver, we have observed a chimeraplast-specific and mitochondrial protein extract dose-dependent growth of dual resistant colonies, ranging from 0.003 ± 0.002% to 0.05 ± 0.002%. This rate of repair in vitro did not differ significantly from that observed in parallel reactions using rat liver nuclear extract. The repair was dependent on the addition of the protein extract and the correct chimeraplast, and was observed at equal frequencies in both RecA and MutS deficient strains. Moreover, both the plasmid and the chimeraplast were incubated separately with the cell-free extracts and the products of these reactions combined before electroporation into the bacteria. No dual resistant colonies were recovered, indicating that the substrates were not capable of reconstituting an active repair system in E. coli. Interestingly, the rate of repair using either the nuclear or mitochondrial extracts did not differ between extracts isolated from quiescent or replicating cells, even though homologous recombination is elevated over 40-fold in regenerating rat liver. 31 Analysis by restriction fragment length polymorphism indicated that some dual antibiotic-resistant colonies contained both repaired and unrepaired plasmids, suggesting that the changes may occur one strand at a time ( Figure 3 ). Since it has been recently reported that the all-DNA strand of the chimeraplast is potentially the one driving the repair reaction, 10 we investigated whether there was an apparent strand preference for nucleotide conversion of the plasmid in the mitochondrial repair reactions. If the mixture of dual and single antibioticresistant plasmids recovered from the repair reactions was a result of the plasmid strand complementary to the all-DNA strand being preferentially repaired, we pre- dicted that there would be a strand bias for correction of the mispaired base. PCR amplification of the plasmids isolated directly from the cell free repair reactions utilizing strand-specific forward primers for the converted nucleotides, and reverse primers in either the antibiotic gene or in the plasmid vector. No particular preference for conversion of one strand of the plasmid by the chimeraplast was observed (Figure 4 ). This suggests that both strands of the plasmid are converted to the sequence carried by the chimeraplast in the mitochondrial cell-free system.
Figure 2 Serum from a Gunn rat before and after treatment with chimeraplasts to repair the frameshift mutation in UGT1A1. (a) Serum from blood of a Gunn
We also developed a cell-free extract assay system based on the correction of a mutant lacZ gene to wildtype. Bacteria transformed with control dual antibioticresistant plasmids exhibited~70% reduction in colonies recovered on medium containing antibiotics other than ampicillin. 30 In the lacZ plasmid-based assay, the number of repaired plasmids (blue color on plates containing Xgal) versus the total number of plasmids recovered (ampicillin resistance) indicates the frequency of repair. The repair of the point mutation also reintroduces an EcoRI restriction endonuclease site, permitting screening by restriction fragment length polymorphism. Recent reports have indicated that short (25 to 50-mer) singlestranded oligonucleotides designed with a single mis- match with their target sequence can mediate site-specific nucleotide conversion. 32, 33 Thus, we utilized this alternate PCR-independent plasmid system and the cell-free extracts from rat liver to determine if a 25-mer singlestranded oligonucleotide designed to correct the mutant lacZ could promote targeted gene repair in vitro. We established that mitochondrial extracts exhibit a dosedependent repair activity (unpublished observations) that was five-fold greater than chimeraplast-mediated repair activity. 27, 30, 34 The increased frequency of repair using single-stranded oligonucleotides rather than chimeraplasts was observed using either nuclear or mitochondrial extracts. Again, no change in repair frequency was observed between extracts isolated from quiescent or proliferating cells. To eliminate the possibility that the observed repair was merely primer extension of the 25-mers using the plasmid as a template, single-stranded oligonucleotides blocked at the 3' end with either an inverted C or a dideoxy nucleotide were used. In both cases, the blocked single-stranded oligonucleotides could not function as a primer for PCR amplification, yet were as active or more than the unblocked 25-mers in promoting conversion of the mutant lacZ gene in vitro.
In conclusion, the site-directed modification of hepatic genomic DNA by chimeraplasts occurs at a level sufficient for therapeutic reduction of a toxic metabolite, bilirubin, in an accurate rodent model of Crigler-Najjar syndrome type 1. The liver may be particularly amenable to this method of targeted gene repair, as a recent study has also reported greater than 25% site-directed conversion of the apoE gene in vivo, using chimeraplasts in a transgenic mouse model. 35 The ability of the chimeraplasts and single-stranded oligonucleotides to mediate site-specific correction of a single nucleotide using extracts from highly purified rat liver mitochondria implies that this organelle contains the endogenous factors necessary for this method of gene repair. In contrast to studies utilizing cell-free extracts from nuclei, or episomal and genomic cell culture studies, 33, 36 allele-specific PCR detected no
Gene Therapy apparent strand bias using mitochondrial extracts for nucleotide conversion. Moreover, the lack of difference in frequency of nucleotide alteration in nuclear and mitochondrial extracts isolated from quiescent and replicating cells suggests that this method of repair may be independent of cell cycle status. The current data suggest that these oligonucleotide-mediated strategies of targeted gene repair offer a significant alternative to traditional gene augmentation. Identification of the essential factors and pathways involved, improvement in the delivery systems, and refinement of the molecular design offer a means to achieve the ultimate goal of gene therapy -the ability to correct the genetic defect and maintain the endogenous regulated control of gene expression.
